rs10063949 — SLC23A1 SLC23A1 variant

SLC23A1 rs10063949 — A Vitamin C Transporter Variant Linked to Intestinal Inflammation

Vitamin C cannot be synthesised by humans — every milligram must be absorbed from diet through specialised transporters in the gut wall and then reclaimed from the urine before it can be lost. The primary gatekeeper in both places is SVCT1¹¹ SVCT1
Sodium-dependent Vitamin C Transporter 1, the protein product of SLC23A1; expressed on the apical (luminal) surface of intestinal enterocytes and renal proximal tubule cells where it drives ascorbate uptake coupled to the sodium electrochemical gradient, encoded by SLC23A1 on chromosome 5. The rs10063949 variant lies in an intron of this gene and has been associated with susceptibility to Crohn disease through a mechanism involving impaired mucosal antioxidant defence.

The Mechanism

rs10063949 sits at position chr5:139,383,837 (GRCh38) within an intron of SLC23A1. Because SLC23A1 is transcribed from the minus strand of chromosome 5, the plus-strand alleles T (reference) and C (alternate) correspond to A and G on the coding strand — which is why publications using minus-strand notation describe this as a T/G or "G allele" variant. The functional consequence of the C allele is not yet characterised at the molecular level; as an intronic change it may affect splicing efficiency, mRNA stability, or regulatory element binding.

What is clear from animal models is that SVCT1 loss is profoundly damaging. Slc23a1 knockout mice²² Slc23a1 knockout mice
Corpe et al. J Clin Invest 2010 excrete up to 18 times more urinary ascorbate than wild-type littermates, losing as much as 70% of their body ascorbate stores daily through the urine. Hepatic portal ascorbate accumulation was nearly abolished. Both knockout and heterozygous pups born to Slc23a1-null dams suffered approximately 45% perinatal mortality, directly attributable to ascorbate insufficiency. This establishes SVCT1 as essential — partial impairment of its function has a measurable impact on circulating and tissue vitamin C levels.

The Evidence

The most direct evidence linking rs10063949 to a clinical outcome comes from a genotyping study in the Manitoba IBD Cohort³³ genotyping study in the Manitoba IBD Cohort
Amir Shaghaghi et al. J Crohns Colitis 2014, which genotyped three SLC23A1 variants (rs6596473, rs33972313, and rs10063949) in 162 Crohn disease patients, 149 ulcerative colitis patients, and 142 controls. The C allele at rs10063949 (reported as the G allele in coding-strand notation) was significantly associated with Crohn disease: heterozygous carriers had OR 2.54 (95% CI: 1.38–4.66) and homozygous carriers had OR 4.72 (95% CI: 2.53–8.81), both P < 0.0001. No association was found with ulcerative colitis. rs6596473 and rs10063949 were in strong linkage disequilibrium (D' = 0.94), and a CGG haplotype spanning the three variants was enriched in CD patients (65.3%) compared to controls (43.5%).

The biological rationale is straightforward: the intestinal mucosa of Crohn disease patients is characterised by elevated oxidative stress, and vitamin C is a major luminal and cellular antioxidant. Variants that reduce SVCT1-mediated ascorbate uptake would deplete mucosal vitamin C reserves, potentially lowering the threshold for oxidative damage and inflammatory cascades. The authors proposed that ascorbate transporter genotyping could guide individualised nutritional supplementation in IBD.

At the population level, the SLC23A1 locus is the strongest common genetic determinant of plasma vitamin C. A meta-analysis of 15,087 participants across 5 UK cohorts⁴⁴ meta-analysis of 15,087 participants across 5 UK cohorts
Timpson et al. Am J Clin Nutr 2010 demonstrated that rare alleles at this locus (principally rs33972313, a missense variant in the same gene) reduce plasma ascorbate by ~6 µmol/L per allele. This locus-level effect was subsequently confirmed in a GWAS of 52,018 Europeans⁵⁵ GWAS of 52,018 Europeans
Zheng et al. Diabetes Care 2021 as the single strongest genetic signal for circulating vitamin C, although Mendelian randomization analysis found no causal link between genetically lower vitamin C and type 2 diabetes risk in that study.

Practical Actions

For CC homozygotes, the combination of genetically reduced SVCT1 activity and chronic inflammatory pressure on mucosal antioxidant reserves makes targeted vitamin C intake a logical priority. The key is ensuring consistent dietary ascorbate supply and considering timing around meals, since SVCT1 is the primary apical intestinal transporter — its capacity is finite, and high single doses (above ~200 mg) are absorbed with diminishing efficiency regardless of genotype. Spreading intake across several servings during the day maximises absorption through the transporter.

CT heterozygotes retain one functional copy of the regulatory region and have intermediate risk; monitoring gastrointestinal symptoms and maintaining adequate vitamin C intake is a prudent precaution.

Interactions

rs10063949 is in strong LD with rs6596473 (D' = 0.94) in the same SLC23A1 gene region. The locus also contains the missense variant rs33972313 (Val264Met), which is the lead GWAS signal for plasma vitamin C reduction and alters the SVCT1 protein directly. Carriers of rs10063949 C allele who also carry the rs33972313 T allele may face compounded SVCT1 impairment affecting both protein function and regulatory expression. The intronic variant rs11950646 (A allele) is a third independent SLC23A1 predictor of plasma vitamin C identified in the EPIC cohort.

The intestinal oxidative stress pathway implicated in rs10063949-associated Crohn disease risk intersects with the broader antioxidant network. SLC23A2 (which encodes SVCT2, the primary transporter in most other tissues including the brain and immune cells) is a related gene worth evaluating in IBD risk contexts; variants in SLC23A2 (rs6133175, rs1279683) have shown independent associations in some populations.